Type 2 diabetes mellitus and cancer: epidemiology, physiopathology and prevention
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Rey-Reñones, Cristina
- dc.contributor.author Baena Díez, Jose M.
- dc.contributor.author Aguilar-Palacio, Isabel
- dc.contributor.author Miquel, Cristina
- dc.contributor.author Grau Magaña, Maria
- dc.date.accessioned 2022-05-20T06:49:27Z
- dc.date.available 2022-05-20T06:49:27Z
- dc.date.issued 2021
- dc.description.abstract Individuals with type 2 diabetes mellitus are at greater risk of developing cancer and of dying from it. Both diseases are age-related, contributing to the impact of population aging on the long-term sustainability of health care systems in European Union countries. The purpose of this narrative review was to describe, from epidemiological, pathophysiological and preventive perspectives, the links between type 2 diabetes mellitus and the most prevalent cancers in these patients. Multiple metabolic abnormalities that may occur in type 2 diabetes mellitus, particularly obesity, could explain the increased cancer risk. In addition, the effectiveness of drugs commonly used to treat type 2 diabetes mellitus (e.g., metformin and thiazolidinediones) has been broadly evaluated in cancer prevention. Thus, a better understanding of the links between type 2 diabetes mellitus and cancer will help to identify the contributing factors and the pathophysiological pathways and to design personalized preventive strategies. The final goal is to facilitate healthy aging and the prevention of cancer and other diseases related with type 2 diabetes mellitus, which are among the main sources of disability and death in the European Union and worldwide.
- dc.format.mimetype application/pdf
- dc.identifier.citation Rey-Reñones C, Baena-Díez JM, Aguilar-Palacio I, Miquel C, Grau M. Type 2 diabetes mellitus and cancer: epidemiology, physiopathology and prevention. Biomedicines. 2021 Oct 9; 9(10): 1429. DOI: 10.3390/biomedicines9101429
- dc.identifier.doi http://dx.doi.org/10.3390/biomedicines9101429
- dc.identifier.issn 2227-9059
- dc.identifier.uri http://hdl.handle.net/10230/53190
- dc.language.iso eng
- dc.publisher MDPI
- dc.rights Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0
- dc.subject.keyword Disease prevention
- dc.subject.keyword Epidemiology
- dc.subject.keyword Metformin
- dc.subject.keyword Neoplasms
- dc.subject.keyword Obesity
- dc.subject.keyword Thiazolidinediones
- dc.subject.keyword Type 2 diabetes mellitus
- dc.title Type 2 diabetes mellitus and cancer: epidemiology, physiopathology and prevention
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion